ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0519

Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid

Rohan Willis1, E Nigel Harris2, Vijaya Murthy3, Zurina Romay-Penabad1, Alvaro Schleh4, Monica Smikle2, Karel De Ceulaer2, Anne Tebo5, Troy Jaskowski6, Marta Guerra7, David Ware Branch8, Jane Salmon7, Michelle Petri9 and Emilio Gonzalez1, 1University of Texas Medical Branch, Galveston, TX, 2University of the West Indies, Kingston, Jamaica, 3University of Texas Medical Branch, League City, TX, 4Antiphospholipid Standardization Laboratory, GALVESTON, TX, 5Department of Pathology, University of Utah, Salt Lake City, 6ARUP Laboratories, Salt Lake City, UT, 7Hospital for Special Surgery, New York, NY, 8University of Utah, Salt Lake City, 9Johns Hopkins University School of Medicine, Baltimore

Meeting: ACR Convergence 2020

Keywords: antiphospholipid syndrome, Autoantibody(ies), Cardiovascular, Diagnostic criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard respectively. The purpose of this study was to evaluate the performance characteristics of non-criteria anti-phosphatidic acid (anti-PA), anti-phosphatidylglycerol (anti-PG) and anti-phosphatidylethanolamine (anti-PE) assays (IgG/IgM) in identifying APS related clinical manifestations in a large group of patients with aPL-related diseases.

Methods: Serum samples from 520 patients from the Hopkins (n=344) and Jamaican SLE cohorts (n=42), the PROMISSE cohort (n=77), as well as APS patients (n=29) and healthy controls (n=28) from the Antiphospholipid Standardization Laboratory were examined for IgG/IgM positivity in aCL (in-house), anti-β2GPI (INOVA Diagnostics), anti-PA, anti-PG and anti-PE (Louisville APL) ELISA assays. Assay cut-offs were aCL IgG/IgM (10GPL/10MPL), anti-β2GPI (20SGU/20SMU), anti-PA, anti-PG, anti-PE (15GPL/15MPL). Correlation of assay positivity with clinical manifestations expressed as odds ratio (OR) with 95%CI, the effect of increasing antibody titers, logistic regression multivariate analysis, quantitative and qualitative inter-assay agreement, and various analytical measures of assay performance including sensitivity, specificity, positive (PPV) and negative (NPV) predictive values were evaluated.

Results: The prevalence of IgG/IgM anti-PA positivity was 30.4%, anti-PG was 27.7%, anti-PE was 30.8%, aCL was 24.2% and anti-β2GPI was 18.3%. The IgG isotypes of all assays were associated with at least one or more thrombotic and/or obstetric manifestation, while IgM isotypes of non-criteria assays were associated with obstetric manifestations. All criteria and non-criteria assays (IgG/IgM) were associated with APS diagnosis (Table 1). There was a 3 to 10-fold increased risk for thrombotic manifestations, particularly venous thrombosis, associated with high vs low positive titers in IgG assays. There was moderate to excellent quantitative and qualitative agreement among most assays of corresponding isotypes. Overall, sensitivity (26.3-39.5%), specificity (85.3-94.1%), PPV (39.3-68.0%) and NPV (70.4-76.1%) for APS diagnosis were relatively similar among IgG assays, which performed better than their IgM counterparts. IgG aCL was the only independent predictor for venous thrombosis OR 3.6(2.1-6.1) and arterial thrombosis OR 1.9(1.1-3.4) while IgG anti-PA was the only independent predictor for placental insufficiency due to pre-eclampsia/eclampsia OR 2.4(1.3-4.6) and recurrent miscarriage OR 1.9(1.2-3.0).

Conclusion: IgG anti-PA, anti-PG and anti-PE antibodies were associated with thrombotic and obstetric APS-related manifestations, while their IgM counterparts were associated with mainly obstetric manifestations. Increasing titers of IgG assays imparted an increased risk, particularly for venous thrombosis. These non-criteria PL assays are promising biomarkers for particular APS manifestations and their independent value in APS classification requires further investigation.

Table 1. Association of antiphospholipid assay positivity with APS-related clinical manifestations – Odds Ratios with 95% Confidence Intervals


Disclosure: R. Willis, Louisville APL Diagnostics Inc, 5, Pfizer, 2; E. Harris, Louisville APL Diagnostics Inc, 4; V. Murthy, None; Z. Romay-Penabad, None; A. Schleh, Louisville APL Diagnostics Inc, 4; M. Smikle, None; K. De Ceulaer, None; A. Tebo, None; T. Jaskowski, None; M. Guerra, None; D. Branch, None; J. Salmon, UCB, 1, 2, BMS, 1, 2, Abbott, 1, Pfizer, 1, Johnson & Johnson, 1, Lilly, 1, Merck, 1, Regeneron, 1; M. Petri, AbbVie, 5, Amgen, 5, AstraZeneca, 2, 5, BMS, 5, Decision Resources, 5, GSK, 2, 5, INOVA, 5, IQVIA, 5, Janssen, 5, Eli Lilly, 2, 5, Merck EMD Serono, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5, Exagen, 2; E. Gonzalez, None.

To cite this abstract in AMA style:

Willis R, Harris E, Murthy V, Romay-Penabad Z, Schleh A, Smikle M, De Ceulaer K, Tebo A, Jaskowski T, Guerra M, Branch D, Salmon J, Petri M, Gonzalez E. Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/thrombotic-and-obstetric-associations-of-non-criteria-antiphospholipid-immunoassays-that-detect-antibodies-to-neutral-and-negatively-charged-phospholipid/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thrombotic-and-obstetric-associations-of-non-criteria-antiphospholipid-immunoassays-that-detect-antibodies-to-neutral-and-negatively-charged-phospholipid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology